University of California, San Francisco
500 Parnassus Ave, San Francisco, CA, 94143, United States
Overview
UCSF scientist over twenty-five (25) years, twenty-three as Director of the Laboratory for Cell Analysis (LCA). Currently Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine. • Built the LCA into one of the largest academic cytometry core facilities worldwide. • Direct contribution to grants totals well over $40M in extramural funding. • Helped design and build five commercial flow cytometers, two cell sorters, and two commercial confocal microscopes. Current work supports several developing technology fields including automated digital pathology and laser-based microdissection systems, next generation clinical cell sorters, spectral flow cytometry, chip-based cytometry and point-of-care devices, wide-field high-resolution deep tissue confocal microscopy, mass spec flow cytometry (CyTOF), and spectral in vivo imaging. Application development includes single cell genomics, new functional reporter probes for cell cycle, cellular biosensors, FRET/FRAP/FLIM reporters for monitoring protein and drug interactions, new encoded carrier technology for immune profiling and liquid arrays, and rapid identification systems for virology and microbiology. Hyun also participates in biomedical software and database design, and testing of new algorithms for cytometric data processing and presentation of results.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Association
- Biotechnology
- Education
- Medical
- Pharmaceutical
Investment portfolio
- ArsenalBio
Participated · Series B · Sep 2022
Arsenal Biosciences develops programmable, autologous T cell therapies using precise CRISPR-mediated insertion of large synthetic DNA cassettes and logic gating to improve tumor targeting. Its full-stack R&D engine and nonviral clinical manufacturing approach aim to generate multifunctional T cell medicines and build a large DNA library of therapeutic integrated circuits. The company is advancing a pipeline that includes programs for ovarian, kidney, and prostate cancers and a collaboration with Bristol-Myers Squibb to co-develop additional solid-tumor candidates. ArsenalBio recently entered the clinic with AB-2100, a second T cell product candidate now in a Phase 1/2 trial for clear-cell renal cell carcinoma, which has received FDA Fast Track designation. The company plans to use new funding to advance lead programs through clinical development, scale manufacturing, and invest in tools and processes for identifying and developing new candidates. ArsenalBio is headquartered in South San Francisco, California. Arsenal Biosciences develops next-generation autologous T cell therapies for solid tumors using precise CRISPR insertion of large synthetic DNA sequences. Its platform generates multifunctional T cell medicines and the company is building an extensive DNA library of therapeutic 'integrated circuits' with logic gating and synthetic features to improve tumor targeting and therapeutic functions. ArsenalBio pairs a computationally driven approach with nonviral clinical manufacturing to pursue enhanced efficacy, safety, and broader access. The company is advancing a pipeline that includes a lead program, AB-1015, for ovarian cancer, with plans to seek FDA IND clearance and first patient dosing later this year. It also has early-stage candidates for kidney, prostate, and other cancer indications. ArsenalBio is headquartered in South San Francisco, California. ArsenalBio is building a programmable cell therapy platform to create more effective and accessible immune cell therapies, initially focused on cancer. The company integrates CRISPR-based genome engineering, scaled high-throughput target identification, synthetic biology, and machine learning to drive discovery and development. ArsenalBio aims to precisely insert significantly larger DNA payloads without viral vectors, encoding broader biological “software” to rewire immune cell circuitry. The approach targets both solid organ and hematologic cancers and seeks to improve efficacy, patient safety, provider costs, and market access. Leadership and scientific founders come from a consortium of academic medical and research institutions and include experienced industry executives in immuno-oncology, cell therapy, and genomics. ArsenalBio was founded in 2019 and is based in South San Francisco.